Codexis' Strategic Focus: Discontinues Biotherapeutics Development, Lays Off 25% Of Employees, Cash Runway Into Mid-2026 - Codexis (NASDAQ:CDXS)
Codexis Inc (NASDAQ: CDXS) intends to prioritize advancing and commercializing its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform and its 
Codexis Inc Codexis Shelves Development Health Science Enzyme Catalyzed Oligonucleotide Pharmaceutical Manufacturing
Source: benzinga.com